We expect CRISPR Therapeutics (CRSP) to surpass expectations when it reports second-quarter 2024 results next month.Let’s see how things have shaped up for the quarter to be reported.Factors to NoteCRISPR Therapeutics’ top line comprises grants and collaboration revenues from its partnership with Vertex Pharmaceuticals (VRTX) .Revenues in the last reported quarter solely comprised revenues from grants. The company did not record any collaboration revenues from Vertex in the first quarter. It remains to be s ...